Characteristics of azathioprine use and cessation in a longitudinal lupus cohort

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

OBJECTIVE: Guidelines for azathioprine (AZA) use in systemic lupus erythematosus (SLE), including indications for initiation and cessation, are lacking. Clinical decision-making could be improved if reasons for cessation of AZA treatment were standardised. METHODS: We determined the characteristics of AZA use in a cohort of patients with SLE and evaluated reasons for AZA cessation. Patients with SLE in a single centre had longitudinal recording of disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI)-2k), laboratory investigations and treatment from 2007 to 2012. RESULTS: Of 183 patients studied, 67 used AZA on at least one occasion. There was no significant difference between AZA users and non-users in age or American College of Rheumatology criteria. Compared with those not treated with AZA, patients treated with AZA had higher disease activity (time-adjusted mean SLEDAI 5.2+/-0.3 vs 3.8+/-0.3, p=0.0028) and damage (Systemic Lupus International Collaborating Clinics (SLICC)-SDI 1.6+/-0.3 vs 1.2+/-0.1, p=0.0445), and were more likely to have a positive dsDNA (p=0.0130) and receive glucocorticoids (p
Original languageEnglish
Pages (from-to)1 - 7
Number of pages7
JournalLupus Science and Medicine
Volume2
DOIs
Publication statusPublished - 2015

Cite this

@article{86b068e10c4c48ebba6248151f165244,
title = "Characteristics of azathioprine use and cessation in a longitudinal lupus cohort",
abstract = "OBJECTIVE: Guidelines for azathioprine (AZA) use in systemic lupus erythematosus (SLE), including indications for initiation and cessation, are lacking. Clinical decision-making could be improved if reasons for cessation of AZA treatment were standardised. METHODS: We determined the characteristics of AZA use in a cohort of patients with SLE and evaluated reasons for AZA cessation. Patients with SLE in a single centre had longitudinal recording of disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI)-2k), laboratory investigations and treatment from 2007 to 2012. RESULTS: Of 183 patients studied, 67 used AZA on at least one occasion. There was no significant difference between AZA users and non-users in age or American College of Rheumatology criteria. Compared with those not treated with AZA, patients treated with AZA had higher disease activity (time-adjusted mean SLEDAI 5.2+/-0.3 vs 3.8+/-0.3, p=0.0028) and damage (Systemic Lupus International Collaborating Clinics (SLICC)-SDI 1.6+/-0.3 vs 1.2+/-0.1, p=0.0445), and were more likely to have a positive dsDNA (p=0.0130) and receive glucocorticoids (p",
author = "Lucy Croyle and Alberta Hoi and Morand, {Eric Francis}",
year = "2015",
doi = "10.1136/lupus-2015-000105",
language = "English",
volume = "2",
pages = "1 -- 7",
journal = "Lupus Science and Medicine",
issn = "2053-8790",
publisher = "BMJ Publishing Group",

}

Characteristics of azathioprine use and cessation in a longitudinal lupus cohort. / Croyle, Lucy; Hoi, Alberta; Morand, Eric Francis.

In: Lupus Science and Medicine, Vol. 2, 2015, p. 1 - 7.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Characteristics of azathioprine use and cessation in a longitudinal lupus cohort

AU - Croyle, Lucy

AU - Hoi, Alberta

AU - Morand, Eric Francis

PY - 2015

Y1 - 2015

N2 - OBJECTIVE: Guidelines for azathioprine (AZA) use in systemic lupus erythematosus (SLE), including indications for initiation and cessation, are lacking. Clinical decision-making could be improved if reasons for cessation of AZA treatment were standardised. METHODS: We determined the characteristics of AZA use in a cohort of patients with SLE and evaluated reasons for AZA cessation. Patients with SLE in a single centre had longitudinal recording of disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI)-2k), laboratory investigations and treatment from 2007 to 2012. RESULTS: Of 183 patients studied, 67 used AZA on at least one occasion. There was no significant difference between AZA users and non-users in age or American College of Rheumatology criteria. Compared with those not treated with AZA, patients treated with AZA had higher disease activity (time-adjusted mean SLEDAI 5.2+/-0.3 vs 3.8+/-0.3, p=0.0028) and damage (Systemic Lupus International Collaborating Clinics (SLICC)-SDI 1.6+/-0.3 vs 1.2+/-0.1, p=0.0445), and were more likely to have a positive dsDNA (p=0.0130) and receive glucocorticoids (p

AB - OBJECTIVE: Guidelines for azathioprine (AZA) use in systemic lupus erythematosus (SLE), including indications for initiation and cessation, are lacking. Clinical decision-making could be improved if reasons for cessation of AZA treatment were standardised. METHODS: We determined the characteristics of AZA use in a cohort of patients with SLE and evaluated reasons for AZA cessation. Patients with SLE in a single centre had longitudinal recording of disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI)-2k), laboratory investigations and treatment from 2007 to 2012. RESULTS: Of 183 patients studied, 67 used AZA on at least one occasion. There was no significant difference between AZA users and non-users in age or American College of Rheumatology criteria. Compared with those not treated with AZA, patients treated with AZA had higher disease activity (time-adjusted mean SLEDAI 5.2+/-0.3 vs 3.8+/-0.3, p=0.0028) and damage (Systemic Lupus International Collaborating Clinics (SLICC)-SDI 1.6+/-0.3 vs 1.2+/-0.1, p=0.0445), and were more likely to have a positive dsDNA (p=0.0130) and receive glucocorticoids (p

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548066/pdf/lupus-2015-000105.pdf

U2 - 10.1136/lupus-2015-000105

DO - 10.1136/lupus-2015-000105

M3 - Article

VL - 2

SP - 1

EP - 7

JO - Lupus Science and Medicine

JF - Lupus Science and Medicine

SN - 2053-8790

ER -